409 related articles for article (PubMed ID: 30658435)
21. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.
Hu Y; Lu X; Chen K; Yan R; Li QS; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(2):903-9. PubMed ID: 22192936
[TBL] [Abstract][Full Text] [Related]
22. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors.
Barnes NG; Parker AW; Ahmed Mal Ullah AA; Ragazzon PA; Hadfield JA
Bioorg Med Chem; 2020 Oct; 28(19):115684. PubMed ID: 32912434
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors.
Romagnoli R; Oliva P; Salvador MK; Camacho ME; Padroni C; Brancale A; Ferla S; Hamel E; Ronca R; Grillo E; Bortolozzi R; Rruga F; Mariotto E; Viola G
Eur J Med Chem; 2019 Nov; 181():111577. PubMed ID: 31400707
[TBL] [Abstract][Full Text] [Related]
27. New Combretastatin Analogs as Anticancer Agents: Design, Synthesis, Microtubules Polymerization Inhibition, and Molecular Docking Studies.
Abdul Hussein SA; Razzak Mahmood AA; Tahtamouni LH; Balakit AA; Yaseen YS; Al-Hasani RA
Chem Biodivers; 2023 Apr; 20(4):e202201206. PubMed ID: 36890635
[TBL] [Abstract][Full Text] [Related]
28. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of new 2-chloro-4-aminopyrimidine and 2,6-dimethyl-4-aminopyrimidine derivatives as tubulin polymerization inhibitors.
Xu S; An B; Li Y; Luo X; Li X; Jia X
Bioorg Med Chem Lett; 2018 Jun; 28(10):1769-1775. PubMed ID: 29673981
[TBL] [Abstract][Full Text] [Related]
31. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
Ducki S; Rennison D; Woo M; Kendall A; Chabert JF; McGown AT; Lawrence NJ
Bioorg Med Chem; 2009 Nov; 17(22):7698-710. PubMed ID: 19837593
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies.
Kumar B; Sharma P; Gupta VP; Khullar M; Singh S; Dogra N; Kumar V
Bioorg Chem; 2018 Aug; 78():130-140. PubMed ID: 29554587
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
34. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
35. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
[TBL] [Abstract][Full Text] [Related]
36. Correlation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues.
Jedhe GS; Paul D; Gonnade RG; Santra MK; Hamel E; Nguyen TL; Sanjayan GJ
Bioorg Med Chem Lett; 2013 Aug; 23(16):4680-4. PubMed ID: 23809851
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors.
El-Zoghbi MS; Bass AK; A Abuo-Rahma GE; Mohamed MF; Badr M; Al-Ghulikah HA; Abdelhafez EM
Future Med Chem; 2024 Apr; 16(7):601-622. PubMed ID: 38436113
[No Abstract] [Full Text] [Related]
38. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
40. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
